Medifast (NYSE:MED) exceeds Q3 2026 expectations, full-year outlook slightly exceeds expectations
Medifast (MED) reported Q3 2026 revenue of $72.05M, beating estimates by 1% but down 19.4% YoY. EPS missed at -$1.57 vs -$0.35 expected. Q4 revenue guidance is $65M, above estimates, with EPS guidance of $0.13, a 204% beat. Full-year EBITDA guidance is $12M, exceeding estimates.
How this was made
The 30-second read
Why it matters
The EPS miss is likely to trigger a sell‑off in the near term, though the upbeat guidance may limit the decline.
Market read
MED's earnings release provides fresh data that can influence trading decisions for the stock and its sector.
What to watch
MED's EBITDA guidance of $12 M versus $4.4 M consensus suggests improving cash flow that may be undervalued.
Background
MEDIFAST is a provider of weight‑management products; its earnings are closely watched by health‑and‑wellness investors.
Ticker impact
MED posted Q3 2026 results, beating revenue estimates but missing EPS expectations, and issued Q4 guidance that tops consensus forecasts.
downward pressure as investors weigh the EPS miss against the modest revenue beat
The GAAP EPS of -$1.57 fell far short of the -$0.35 consensus, a material miss that typically outweighs a 1% revenue beat.
Market effects
Weight‑loss and nutrition sector may see modest pressure as MED's earnings miss highlights margin challenges.
U.S. small‑cap market could see slight pullback from MED's underperformance.
Limited; impact confined to U.S. equity markets.
Counterpoint
The revenue beat and strong Q4 guidance could support a rebound if investors focus on top‑line momentum.
Key entities
- CompanyMedifast
U.S. listed weight‑management firm (NYSE:MED).
